Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ICER
ICER
Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say
Fierce Pharma
Tue, 05/18/21 - 11:14 am
ICER
drug pricing
corporate citizenship
Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
Endpoints
Thu, 05/6/21 - 10:57 am
Biogen
aducanumab
Alzheimer's disease
drug pricing
ICER
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
BioPharma Dive
Tue, 04/6/21 - 11:00 pm
Bristol Myers Squibb
Bluebird Bio
ICER
Multiple Myeloma
CAR-T
Drug price hikes without new evidence upped spending by $1.2B, ICER says
MedCity News
Wed, 01/20/21 - 11:15 pm
drug pricing
ICER
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
BioPharma Dive
Thu, 06/25/20 - 07:25 pm
Gilead Sciences
remdesivir
ICER
drug pricing
steriod
Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
Endpoints
Tue, 04/28/20 - 10:56 am
Vertex Pharmaceuticals
drug pricing
cystic fibrosis
ICER
What can Linux and Mozilla teach ICER about how to do drug value assessments?
Pharmaforum
Mon, 04/6/20 - 10:35 am
ICER
drug value assessments
New sickle cell drugs priced too high, ICER says
BioPharma Dive
Fri, 03/13/20 - 12:43 pm
sickle cell disease
drug pricing
ICER
Novartis
Global Blood Therapeutics
RWE
Adakveo
Oxbryta
In final report, ICER appears to have a change of heart on new acute migraine therapies
Endpoints
Tue, 02/25/20 - 10:40 am
ICER
migraines
Biohaven
Allergan
ubrogepant
rimegepant
Eli Lilly
Lasmiditan
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
Fri, 01/24/20 - 10:30 am
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
Xtalks
Tue, 12/10/19 - 10:35 am
Novo Nordisk
Rybelsus
oral semaglutide
diabetes
ICER
drug pricing
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
Sat, 11/30/19 - 11:02 pm
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
ICER draws new gene therapy pricing framework
Biopharma Dive
Thu, 11/14/19 - 10:40 am
ICER
gene therapy
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
Forbes
Sun, 11/3/19 - 11:24 pm
insurers
transparency
formulary
ICER
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
Endpoints
Fri, 10/18/19 - 10:18 am
ICER
drug pricing
JNJ
Xarelto
Amarin
Vascepa
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
Fri, 10/11/19 - 11:53 am
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
Tue, 10/8/19 - 09:23 am
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
Wed, 10/2/19 - 11:53 am
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Wed, 09/11/19 - 11:41 pm
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
Thu, 07/11/19 - 12:03 pm
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Pages
« first
‹ previous
1
2
3
4
next ›
last »